SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as shareholders weigh a cryptic message from CEO Dr. Patrick Soon-Shiong about "strengthening the balance sheet" and "recharging for global expansion," which has sparked intense debate over whether it signals non-dilutive funding or future share dilution. The community is actively discussing the potential for international partnerships, particularly in the Middle East and Europe, while expressing frustration over ongoing short-seller activity and legal challenges.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is experiencing significant downward pressure as investors rotate out of AI-linked semiconductor stocks following reports of Googles new memory-compression algorithm, TurboQuant, which fueled concerns about future demand for memory chips. The community remains deeply divided, with some investors panic-selling into a deepening technical breakdown while others aggressively argue the stock is a long-term value play, pointing to historical earnings strength and arguing that current volatility is driven by macro-headwinds and market manipulation rather than fundamental flaws.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is rallying in after-hours trading following reports that the U.S. is prepared to conclude military operations against Iran even if the Strait of Hormuz remains closed. While the news sparked an immediate surge in equity futures and a cooling in oil prices, the community remains deeply divided, with many traders debating whether this is a genuine de-escalation or a tactical 'pump and dump' setup ahead of potential further conflict.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense social media debate, driven by skepticism over its ongoing Bitcoin treasury strategy and concerns about the dilutive impact of capital raises. While some traders continue to capitalize on the stock's high-beta sensitivity to Bitcoin price action, others are actively betting against the company, citing long-term sustainability risks and the aggressive issuance of equity and debt.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is currently a focal point for investors as they navigate high volatility and institutional positioning ahead of upcoming Medicare Advantage rate announcements. The community is sharply divided, with some betting on a major bounce and institutional accumulation while others remain skeptical due to ongoing regulatory scrutiny and persistent macroeconomic headwinds.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is trending due to heightened community speculation surrounding a potential SpaceX IPO and the company's recent operational updates, including a strategic partnership with Mu-G Technologies for microgravity missions. While bulls highlight the stock's low float and potential for a short squeeze alongside broader space sector growth, bears remain skeptical, citing leadership turnover and a lack of revenue as significant red flags.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as investors highlight its role as essential DeFi infrastructure, particularly following its partnership with the U.S. Department of Commerce to provide macroeconomic data on-chain. Community sentiment is driven by the project's institutional backing, its revenue-sharing model through token buybacks, and its role as a core player in the emerging Real World Asset (RWA) sector.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The SPDR Dow Jones Industrial Average ETF (DIA) is trading amidst extreme volatility as investors closely monitor contradictory reports regarding potential peace talks between the U.S. and Iran. The market is reacting sharply to headlines about the Strait of Hormuz and potential shifts in military strategy, fueling a intense tug-of-war between bears betting on further geopolitical escalation and bulls anticipating a breakthrough.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as investors debate the impact of potential regulatory delays and upcoming token unlocks on the asset's price, while community members remain divided between long-term institutional adoption narratives and short-term volatility concerns. The conversation is dominated by contrasting perspectives on Ripple's strategic direction and the timing of the U.S. Clarity Act, with many active traders closely monitoring macro factors and institutional sentiment.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending as investors react to a robust earnings beat and the unveiling of a significant, high-value program award in its space and missile defense pipeline. The community is actively debating the company's long-term growth trajectory in autonomous drone and hypersonic sectors, weighing the impact of conservative management guidance against the ongoing demand driven by elevated geopolitical tensions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Piper Sandler reiterated $CNTA Overweight-$38 and said, There are two main catalysts for CNTA shares this quarter. 
$ALKS $TAK $HRMY $ESALY 
Piper Sandler added, First, the company expects to start Phase 3 trials testing ORX750 in NT1, NT2, and IH. 
 
Second, CNTA expects to provide add&#39;l data from the ongoing CRYSTAL-1 Phase 2 trial. 
 
We should receive data from at least one of the three indication cohorts. 
 
Of the three indications, we believe the most underappreciated question for investors is if orexin agonists can translate meaningfully into idiopathic hypersomnia (IH), a biologically heterogeneous indication that may ultimately represent a larger market opportunity than narcolepsy type 1 (NT1) or type 2 (NT2). 
 
Despite significant unmet need, IH remains a &quot;black box&quot; for the field. 
 
As such, even modest efficacy signals in IH could materially shift investor perception around the breadth of ORX750&#39;s opportunity and provides asymmetric risk-reward.

TD Cowen reiterated $CNTA at a Buy rating and said, As We Await Higher Dose Data For &#39;750, Stock Pullback Is A Good Entry Point 
$ALKS $TAK $ESALY $HRMY 
TD Cowen went on to say: https://x.com/Quantumup1/status/2011547696134307872?s=20

TD Cowen reiterated $CNTA at a Buy rating and said, As We Await Higher Dose Data For '750, Stock Pullback Is A Good Entry Point$ALKS $TAK ESALY HRMYTD Cowen additionally said, We view the recent pullback as a good opportunity, as early '750 Phlla data in NT1, NT2 & IH suggest a...

quantumup on X (formerly Twitter): "TD Cowen reiterated $CNTA at a Buy rating and said, As We Await Higher Dose Data For '750, Stock Pullback Is A Good Entry Point$ALKS $TAK ESALY HRMYTD Cowen additionally said, We view the recent pullback as a good op...

StockTwits Web

Centessa Pharmaceuticals PLC - ADR

Alkermes plc

Takeda Pharmaceutical Co Ltd (ADR)

Eisai Co Ltd - ADR

Harmony Biosciences Holdings Inc

Quantumup

Wolfe Research🏁 $CNTA Outperform/$40, and said, The Next Big Idea in CNS - A High-Conviction Orexin Play; Initiate with OP; $40 PT 
$ALKS $TAK $HRMY $ESALY 
Wolfe Research added, While multiple orexin-2 agonists demonstrated strong clinical data in late-stage studies, we believe CNTA&#39;s ORX750 would become the best-in-class product and generate &gt;$3B US peak sales 
 
➢ Key upcoming catalysts: Additional Ph2 data for higher doses expected in 1Q26, we expect good data which should move the stock up significantly (+40-50%).

 Overweight-$38 and said, There are two main catalysts for CNTA shares this quarter. 


 
Piper Sandler added, First, the company expects to start Phase 3 trials testing ORX750 in NT1, NT2, and IH. 
 
Second, CNTA expects to provide add'l data from the ongoing CRYSTAL-1 Phase 2 trial. 
 
We should receive data from at least one of the three indication cohorts. 
 
Of the three indications, we believe the most underappreciated question for investors is if orexin agonists can translate meaningfully into idiopathic hypersomnia (IH), a biologically heterogeneous indication that may ultimately represent a larger market opportunity than narcolepsy type 1 (NT1) or type 2 (NT2). 
 
Despite significant unmet need, IH remains a "black box" for the field. 
 
As such, even modest efficacy signals in IH could materially shift investor perception around the breadth of ORX750's opportunity and provides asymmetric risk-reward.